Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry

CONCLUSIONS: Infections, herpes zoster and gastrointestinal adverse events in patients with RA tended to be more frequent with JAKi. However, prognosis was poor in patients receiving JAKi. Persistence was similar for TNFi and JAKi, although factors associated with discontinuation differed by diagnostic group.PMID:38594056 | DOI:10.1136/ard-2023-225271

Source: Herpes - April 9, 2024 Category: Infectious Diseases Authors: Blanca Hern ández-Cruz Luc ía Otero-Varela Mercedes Freire-Gonz ález Noem í Busquets-Pérez Alfredo Javier Garc ía González Manuel Moreno-Ramos Juan Maria Blanco-Madrigal Sara Manrique-Arija Eva Perez-Pampin Dolores Ruiz-Montesino Fernando S ánchez Source Type: research